- Conditions
- Long COVID, Neurodegeneration, Reproductive Disorder, SARS-CoV 2
- Interventions
- Kisspeptin 112-121
- Drug
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Condition Directory
Long COVID clinical trials
Directory of U.S. ClinicalTrials.gov public records for Long COVID. Browse Long COVID recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced May 21, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
80
Shown on this page
12
Local recruiting
32
Local phase groups
6
How Long COVID studies are organized in the registry
Terminology for this condition is unusually inconsistent across the registry: the same kind of study may be filed under “long COVID,” “post-acute sequelae of SARS-CoV-2,” the abbreviation PASC, or “post-COVID conditions.” Trying more than one of these terms is the single most effective way to avoid missing records.
- 40% of the 80 locally indexed Long COVID records are currently marked recruiting.
- The most common phase group in the local index is Phase 2 (32 records).
- The most frequent sponsor is Duke University (7 records).
- The most listed study location is New York, New York (12 records).
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 80 matching trials for Long COVID.
Indexed local directory records.
Phase distribution
Phase 2 32
Not applicable 30
Phase 1 5
Phase 3 5
Early Phase 1 1
Phase 4 1
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Long COVID, Long COVID Syndrome, Long Covid 19
- Interventions
- Anktiva
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Long COVID
- Interventions
- N-803 (IL-15 Superagonist)
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- COVID-19, Coronavirus Infections, Long COVID, Sars-CoV-2 Infection
- Interventions
- Baricitinib, Placebo
- Drug · Other
- Lead sponsor
- Wes Ely
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Brain Fog, Cognitive Dysfunction, Cognitive Impairment, Long COVID, Post-Acute COVID-19 Syndrome
- Interventions
- Follow Up Phone Calls, In-lab Brain Health Training, In-lab Instrumental Activities of Daily Living Training, Peer Mentoring, Processing Speed Training, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity, Transfer Package, Vocational Rehabilitation
- Behavioral · Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Long COVID
- Interventions
- Pirfenidone, Placebo for pirfenidone, Placebo for upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- Douglas D. Fraser
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Long COVID, Olfactory Disorder, Smell Dysfunction
- Interventions
- Active Smell Training (ST), Placebo Smell Training (PBO), Trigeminal Nerve Stimulation (TNS)
- Other · Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Long COVID, Neuro-PASC
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Mountain Home, Tennessee
- Conditions
- Long Covid
- Interventions
- Placebo, Selzentry, tenofovir disoproxil/emtricitabine
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Fatigue Syndrome, Long Covid, Myalgic Encephalomyelitis, Post-treatment Lyme Disease Syndrome
- Interventions
- Lumbrokinase
- Dietary Supplement
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Long COVID, Post Acute Sequelae of COVID-19
- Interventions
- 11C-PS13
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Long COVID
- Interventions
- NE3107, Placebo
- Drug
- Lead sponsor
- BioVie Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 16 more
About this Long COVID clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Long COVID as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Long COVID.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Long COVID.